Tags: Drug.

Pasireotide (SOM230 trade name Signifor) is an orphan drug approved in the U.S. and Europe for the treatment of Cushing’s disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis.

Pasireotide.svg
ATC prefix
H01
ATC suffix
CB05
CAS number
396091-73-9
ChEBI
72312
FDA UNII code
98H1T17066
IUPAC name
[(3S6S9S12R15S18S20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-258111417-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-147101316-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate
PubChem
9941444

Loading...

This page contains content from the copyrighted Wikipedia article "Pasireotide"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.